Document Detail


Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin.
MedLine Citation:
PMID:  23293889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plants have long been providing mankind with remedies of different ailments. Flavonoids, a family of naturally occurring polyphenolic compounds are ubiquitous in plants. Development of polyphenol-based drugs has not attracted much attention by researchers and drug companies. Therefore, despite extensive studies on polyphenols, this vast group of compounds is underrepresented in clinical medicine. Fisetin (3,7,3',4'-tetrahydroxyflavone) belongs to the flavonol subgroup of flavonoids together with quercetin, myricetin and kaempferol and is found in several fruits and vegetables including strawberries, apples, persimmons and onions. Fisetin is showing promise as a useful natural agent against cancer and has been evaluated for its potential inhibitory role against cancer in several in vitro and in vivo studies. The Akt/mTOR pathway is known to play a central role in various cellular processes that contribute to the malignant phenotype. Accordingly, inhibition of this signaling cascade has been a focus of recent therapeutic studies. Novel inhibitors of PI3-K, Akt, and mTOR are now passing through early phase clinical trials. Herein, we review the effect of fisetin on the PI3- K/Akt/mTOR pathway as studied in different cancer cell models.
Authors:
Deeba N Syed; Vaqar M Adhami; Mohammad Imran Khan; Hasan Mukhtar
Related Documents :
400659 - Immunobiology of head and neck cancer: basic concepts.
23706029 - Gender differences in attitudes impeding colorectal cancer screening.
24276469 - Screening for oral cancer: u.s. preventive services task force recommendation statement.
22935209 - Cervical cancer: prevention and treatment.
23889049 - Anti cancer activity on graviola, an exciting medicinal plant extract vs various cancer...
16001959 - Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen de...
11166619 - The bicalutamide early prostate cancer program. demography.
17182479 - Breast cancer survivorship: expressed needs of black women.
11393979 - Platinum and rhodium concentrations in airborne particulate matter in germany from 1988...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Anti-cancer agents in medicinal chemistry     Volume:  13     ISSN:  1875-5992     ISO Abbreviation:  Anticancer Agents Med Chem     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-07-29     Completed Date:  2014-02-13     Revised Date:  2014-04-15    
Medline Journal Info:
Nlm Unique ID:  101265649     Medline TA:  Anticancer Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  995-1001     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents, Phytogenic / pharmacology*
Flavonoids / pharmacology*
Humans
Neoplasms / drug therapy*,  metabolism
Phosphatidylinositol 3-Kinases / metabolism
Proto-Oncogene Proteins c-akt / metabolism*
Signal Transduction / drug effects*
TOR Serine-Threonine Kinases / metabolism*
Grant Support
ID/Acronym/Agency:
P30 CA014520/CA/NCI NIH HHS; R01 CA 160867/CA/NCI NIH HHS; R01 CA160867/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Flavonoids; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; OO2ABO9578/fisetin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Application of Fungal Beta-glucans for the Treatment of Colon Cancer.
Next Document:  Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents.